彩票小胖竞彩旗舰

彩票有几个球几个数

Home/Investors/ Press Releases
5Nov

CymaBay Reports Third Quarter 2020 Financial Results and Provides Corporate Update彩票有几个球几个数

5Nov

CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabetes彩票有几个球几个数

2Nov

CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020彩票有几个球几个数

30Oct

CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020彩票有几个球几个数

1Oct

CymaBay Therapeutics to Present Data from its Phase 2 Study of Seladelpar in Patients with NASH at The Liver Meeting® 2020彩票有几个球几个数

3Sep

CymaBay Therapeutics to Present at Upcoming Investor Conferences彩票有几个球几个数

27Aug

CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study in Primary Biliary Cholangitis at The Digital International Liver Congress™ 2020彩票有几个球几个数

20Aug

CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress™ 2020彩票有几个球几个数

10Aug

CymaBay Reports Second Quarter 2020 Financial Results and Provides Corporate Update彩票有几个球几个数

3Aug

CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020彩票有几个球几个数

3Aug

CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis彩票有几个球几个数

23Jul

FDA Lifts All Clinical Holds on Seladelpar彩票有几个球几个数

19Jun

CymaBay Therapeutics Presents Data at Digestive Disease Week 2020 Online Education彩票有几个球几个数

5Jun

Notice of Change of Location of Annual Meeting of Stockholders to be Held on June 23, 2020彩票有几个球几个数

11May

CymaBay Reports First Quarter 2020 Financial Results and Provides Corporate Update彩票有几个球几个数

4May

CymaBay Therapeutics to Report First Quarter 2020 Financial Results on Monday, May 11彩票有几个球几个数

13Mar

CymaBay Therapeutics Comments on Engine Capital Director Nominations彩票有几个球几个数

12Mar

CymaBay Reports Fourth Quarter and Fiscal Year End 2019 Financial Results and Provides Corporate Update彩票有几个球几个数

5Mar

CymaBay Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 12彩票有几个球几个数

29Jan

CymaBay Publishes Shareholder Letter彩票有几个球几个数

25Nov

CymaBay Therapeutics Halts Clinical Development of Seladelpar彩票有几个球几个数

14Nov

CymaBay Therapeutics to Present at Upcoming Investor Conferences彩票有几个球几个数

5Nov

CymaBay Reports Third Quarter 2019 Financial Results and Provides Corporate Update彩票有几个球几个数

4Nov

CymaBay Therapeutics Reaches Target Enrollment in the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis彩票有几个球几个数

28Oct

CymaBay Therapeutics to Report Third Quarter 2019 Financial Results on Tuesday, November 5彩票有几个球几个数

14Oct

CymaBay Therapeutics to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference彩票有几个球几个数

1Oct

CymaBay Therapeutics Announces Presentations at The Liver Meeting® 2019彩票有几个球几个数

30Sep

CymaBay Therapeutics to Present at the 2019 Cantor Global Healthcare Conference彩票有几个球几个数

17Sep

CymaBay Therapeutics Announces Departure of Chief Medical Officer彩票有几个球几个数

3Sep

CymaBay Therapeutics to Present at Upcoming Investor Conferences in September彩票有几个球几个数

7Aug

CymaBay Reports Second Quarter 2019 Financial Results and Provides Corporate Update彩票有几个球几个数

5Aug

CymaBay Therapeutics Strengthens Management Team with Appointment of Janet Dorling as Chief Commercial Officer彩票有几个球几个数

31Jul

CymaBay Therapeutics to Report Second Quarter 2019 Financial Results on Wednesday, August 7彩票有几个球几个数

18Jun

CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis彩票有几个球几个数

17Jun

CymaBay Therapeutics to Participate in the Raymond James Life Sciences and MedTech Conference彩票有几个球几个数

11Jun

CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis彩票有几个球几个数

20May

CymaBay Therapeutics Presents Data in Patients with Primary Biliary Cholangitis at DDW 2019彩票有几个球几个数

8May

CymaBay Reports First Quarter 2019 Financial Results and Provides Corporate Update彩票有几个球几个数

8May

CymaBay Therapeutics Announces Multiple Presentations at DDW 2019彩票有几个球几个数

30Apr

CymaBay Therapeutics to Report First Quarter 2019 Financial Results on Wednesday, May 8彩票有几个球几个数

12Apr

CymaBay Therapeutics Presents Positive Phase 2 Data for Seladelpar in Patients with Primary Biliary Cholangitis at the International Liver Congress™ 2019彩票有几个球几个数

27Mar

CymaBay Therapeutics Announces Multiple Presentations During The International Liver Conference™ 2019彩票有几个球几个数

12Mar

CymaBay Therapeutics to Present at Upcoming Investor Conferences in March彩票有几个球几个数

11Mar

CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares彩票有几个球几个数

6Mar

CymaBay Announces Pricing of Public Offering of Common Stock彩票有几个球几个数

5Mar

CymaBay Announces Proposed Public Offering of Common Stock彩票有几个球几个数

28Feb

CymaBay Reports Fourth Quarter and Fiscal Year End 2018 Financial Results and Provides Corporate Update彩票有几个球几个数

21Feb

CymaBay Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results on Thursday, February 28彩票有几个球几个数

20Feb

CymaBay Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference彩票有几个球几个数

19Feb

CymaBay Therapeutics Announces Early Enrollment of a Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis彩票有几个球几个数

15Feb

CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis彩票有几个球几个数

2Jan

CymaBay Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference彩票有几个球几个数

20Nov

CymaBay Therapeutics to Participate in Upcoming Investor Conferences彩票有几个球几个数

13Nov

CymaBay Therapeutics Presents Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC at The Liver Meeting® 2018彩票有几个球几个数

6Nov

CymaBay Reports Third Quarter 2018 Financial Results and Provides Corporate Update彩票有几个球几个数

30Oct

CymaBay to Report Third Quarter 2018 Financial Results on Tuesday, November 6彩票有几个球几个数

30Oct

CymaBay Announces the Initiation of the Seladelpar Global Phase 3 Registration Study (ENHANCE) for the Treatment of Primary Biliary Cholangitis and Additional Corporate Updates彩票有几个球几个数

3Oct

CymaBay Therapeutics Announces Additional Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC will be Presented During the Late-Breaking Session at The Liver Meeting®彩票有几个球几个数

24Sep

CymaBay Therapeutics to Participate in Upcoming Investor Conferences in October彩票有几个球几个数

14Aug

CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September彩票有几个球几个数

9Aug

CymaBay Reports Second Quarter 2018 Financial Results and Provides Corporate Update彩票有几个球几个数

2Aug

CymaBay to Report Second Quarter 2018 Financial Results on Thursday, August 9彩票有几个球几个数

25Jun

CymaBay Therapeutics Added to the Russell 3000® and Russell 2000® Indexes彩票有几个球几个数

19Jun

CymaBay Therapeutics to Host Analyst and Investor Day on June 26, 2018彩票有几个球几个数

8May

CymaBay Reports First Quarter 2018 Financial Results and Provides Corporate Update彩票有几个球几个数

8May

CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis彩票有几个球几个数

1May

CymaBay to Report First Quarter 2018 Financial Results on Tuesday, May 8彩票有几个球几个数

11Apr

CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2018彩票有几个球几个数

15Mar

CymaBay Reports Fourth Quarter and Fiscal 2017 Financial Results and Provides Corporate Update彩票有几个球几个数

6Mar

CymaBay to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 15彩票有几个球几个数

5Mar

CymaBay Therapeutics to Participate in Upcoming Investor Conferences in March彩票有几个球几个数

6Feb

CymaBay Therapeutics to Participate in Investor Conferences in February彩票有几个球几个数

1Feb

CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares彩票有几个球几个数

30Jan

CymaBay Announces Pricing of Public Offering of Common Stock彩票有几个球几个数

29Jan

CymaBay Announces Proposed Public Offering of Common Stock彩票有几个球几个数

8Jan

Enrollment Begins in Long-Term Extension Study of Seladelpar in Patients with Primary Biliary Cholangitis彩票有几个球几个数

8Jan

CymaBay Therapeutics Receives $5 Million Milestone Payment for Arhalofenate from Kowa Pharmaceuticals America彩票有几个球几个数

2Jan

CymaBay Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference彩票有几个球几个数

4Dec

CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel彩票有几个球几个数

13Nov

CymaBay Therapeutics to Present at Three Investor Conferences彩票有几个球几个数

8Nov

CymaBay Reports Third Quarter 2017 Financial Results and Corporate Updates彩票有几个球几个数

1Nov

CymaBay to Report Third Quarter 2017 Financial Results on Wednesday, November 8彩票有几个球几个数

31Oct

CymaBay Announces the Appointment of Sujal Shah as President and Chief Executive Officer彩票有几个球几个数

23Oct

CymaBay to Host Post-AASLD Key Opinion Leader Meeting on Novel Treatments for Primary Biliary Cholangitis彩票有几个球几个数

9Oct

CymaBay Announces Oral Late-Breaking Presentation of Interim Results from an Ongoing Phase 2 Study of Patients with Primary Biliary Cholangitis at the AASLD 2017 Liver Meeting彩票有几个球几个数

18Sep

CymaBay Therapeutics to Present at Two Investor Conferences彩票有几个球几个数

11Sep

CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis彩票有几个球几个数

15Aug

CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology彩票有几个球几个数

10Aug

CymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update彩票有几个球几个数

7Aug

CymaBay to Report Second Quarter 2017 Financial Results on Thursday, August 10彩票有几个球几个数

24Jul

CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares彩票有几个球几个数

19Jul

CymaBay Announces Pricing of Public Offering of Common Stock彩票有几个球几个数

17Jul

CymaBay Announces Proposed Public Offering of Common Stock彩票有几个球几个数

17Jul

CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis彩票有几个球几个数

26Jun

CymaBay Announces the Appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality Assurance and the Promotion of Daniel Menold to Vice President, Finance彩票有几个球几个数

11May

CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update彩票有几个球几个数

4May

CymaBay to Report First Quarter 2017 Financial Results on Thursday, May 11彩票有几个球几个数

13Apr

CymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017彩票有几个球几个数

30Mar

CymaBay Therapeutics to Present at Two Investor Conferences in April彩票有几个球几个数

29Mar

CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D.彩票有几个球几个数

23Mar

CymaBay Reports Fourth Quarter and Year End 2016 Financial Results彩票有几个球几个数

16Mar

CymaBay to Report Fourth Quarter And Year End 2016 Financial Results on Thursday, March 23彩票有几个球几个数

9Mar

CymaBay Therapeutics to Present at Two Investor Conferences in March彩票有几个球几个数

7Feb

CymaBay Therapeutics to Present at the 2017 BIO CEO & Investor Conference彩票有几个球几个数

2Feb

CymaBay Announces Pricing of Public Offering of Common Stock彩票有几个球几个数

1Feb

CymaBay Announces Proposed Public Offering of Common Stock彩票有几个球几个数

5Jan

CymaBay Therapeutics Announces Successful Completion of Scientific Advice Discussions with the European Medicines Agency for Arhalofenate彩票有几个球几个数

3Jan

CymaBay Announces Exclusive Licensing Agreement with Kowa Pharmaceuticals America, Inc. for the Development and Commercialization of Arhalofenate in the United States彩票有几个球几个数

8Dec

CymaBay Announces the Appointments of Robert Booth, Ph.D. and Caroline Loewy to Its Board of Directors彩票有几个球几个数

7Dec

CymaBay Therapeutics Announces the Initiation of its Next Phase 2 Study of Seladelpar (MBX-8025) in Patients with Primary Biliary Cholangitis彩票有几个球几个数

6Dec

CymaBay Therapeutics Announces that the Recommended International Nonproprietary Name for MBX-8025 is Seladelpar彩票有几个球几个数

28Nov

CymaBay Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference彩票有几个球几个数

10Nov

CymaBay to Host Key Opinion Leader Meeting on Primary Biliary Cholangitis in New York City彩票有几个球几个数

10Nov

CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 for the Treatment of Primary Biliary Cholangitis彩票有几个球几个数

9Nov

CymaBay Reports Third Quarter 2016 Financial Results彩票有几个球几个数

9Nov

CymaBay Therapeutics Announces a Newly Issued U.S. Patent for the Use of MBX-8025 as a Treatment for Primary Biliary Cholangitis (PBC)彩票有几个球几个数

2Nov

CymaBay to Announce Third Quarter 2016 Financial Results on Wednesday, November 9彩票有几个球几个数

20Oct

CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting彩票有几个球几个数

20Oct

CymaBay Therapeutics Announces that MBX-8025 has Received European Medicines Agency PRIority MEdicines (PRIME) Designation for the Treatment of Primary Biliary Cholangitis彩票有几个球几个数

11Oct

CymaBay Therapeutics Announces a Newly Issued U.S. Patent for MBX-8025 for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)彩票有几个球几个数

6Oct

CymaBay Therapeutics Announces an Oral Presentation Describing the Efficacy of MBX-8025 in a Preclinical Model of NASH at the AASLD 2016 Liver Meeting彩票有几个球几个数

5Oct

CymaBay Therapeutics Announces Plans to Initiate Its Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis彩票有几个球几个数

8Sep

CymaBay Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference彩票有几个球几个数

9Aug

CymaBay Reports Second Quarter 2016 Financial Results彩票有几个球几个数

2Aug

CymaBay to Announce Second Quarter 2016 Financial Results on Tuesday, August 9彩票有几个球几个数

7Jul

CymaBay Announces Participation at Cantor Fitzgerald Healthcare Conference on July 12th in New York彩票有几个球几个数

31May

CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)彩票有几个球几个数

19May

CymaBay Therapeutics to Present at UBS Global Healthcare Conference彩票有几个球几个数

11May

CymaBay Reports First Quarter 2016 Financial Results彩票有几个球几个数

2May

CymaBay to Announce First Quarter 2016 Financial Results on Wednesday, May 11彩票有几个球几个数

29Mar

CymaBay Reports Fourth Quarter and Full Year 2015 Financial Results彩票有几个球几个数

28Mar

CymaBay Announces the Appointment of Paul F. Truex and Robert J. Weiland to its Board of Directors彩票有几个球几个数

28Mar

CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study Manuscript in Arthritis and Rheumatology彩票有几个球几个数

22Mar

CymaBay Announces the Appointment of Dr. Evan Stein, M.D., Ph.D., to its Board of Directors彩票有几个球几个数

21Mar

CymaBay to Announce Fourth Quarter and Year-End 2015 Financial Results on Tuesday, March 29彩票有几个球几个数

17Mar

CymaBay Therapeutics Announces Positive Results from its Pilot Phase 2 Clinical Study of MBX-8025 in Patients with Homozygous Familial Hypercholesterolemia彩票有几个球几个数

3Mar

CymaBay Therapeutics to Present at Two Upcoming Investor Conferences in March彩票有几个球几个数

2Feb

CymaBay Therapeutics to Present at the BIO CEO & Investor Conference彩票有几个球几个数

20Jan

CymaBay Therapeutics Announces Successful Completion of End-of-Phase 2 Discussions With FDA for Arhalofenate彩票有几个球几个数

6Jan

CymaBay Therapeutics to Present at the Biotech Showcase 2016彩票有几个球几个数

13Nov

CymaBay Announces Participation at Three Upcoming Investor Conferences彩票有几个球几个数

12Nov

CymaBay Announces Third Quarter Financial Results彩票有几个球几个数

10Nov

CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis彩票有几个球几个数

5Nov

CymaBay Therapeutics to Present Results From Two Arhalofenate Phase 2 Studies at the American College of Rheumatology (ACR) Annual Meeting, November 6 - 11彩票有几个球几个数

4Nov

CymaBay to Announce Third Quarter 2015 Financial Results on Thursday, November 12彩票有几个球几个数

8Oct

CymaBay Announces the Appointment of Robert J. Wills, Ph.D., as Chairman of the Board of Directors彩票有几个球几个数

3Sep

CymaBay Therapeutics to Present at the Rodman & Renshaw 17th Annual Global Investment Conference彩票有几个球几个数

10Aug

CymaBay Announces Second Quarter 2015 Financial Results彩票有几个球几个数

6Aug

CymaBay Strengthens the Intellectual Property of Arhalofenate With Issuance of Two New Patents彩票有几个球几个数

3Aug

CymaBay to Announce Second Quarter 2015 Financial Results on Monday, August 10彩票有几个球几个数

27Jul

CymaBay Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares彩票有几个球几个数

15Jul

CymaBay Therapeutics Announces Pricing of $20 Million Public Offering of Common Stock彩票有几个球几个数

14Jul

CymaBay Announces Proposed Public Offering of Common Stock彩票有几个球几个数

6Jul

CymaBay Therapeutics to Present at the Cantor Fitzgerald Inaugural Healthcare Conference彩票有几个球几个数

12Jun

CymaBay Therapeutics Presents Poster at EULAR 2015彩票有几个球几个数

29May

CymaBay to Present at the Jefferies 2015 Global Healthcare Conference彩票有几个球几个数

15May

CymaBay to Present at the 2015 UBS Global Healthcare Conference彩票有几个球几个数

7May

CymaBay Reports First Quarter 2015 Financial Results彩票有几个球几个数

1May

CymaBay to Announce First Quarter 2015 Financial Results on Thursday, May 7, 2015彩票有几个球几个数

23Apr

CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia彩票有几个球几个数

22Apr

CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia彩票有几个球几个数

20Apr

CymaBay Therapeutics Strengthens Management Team With the Appointment of Kirk Rosemark to VP, Regulatory Affairs and Quality Assurance彩票有几个球几个数

7Apr

CymaBay to Present at the 14th Annual Needham Healthcare Conference彩票有几个球几个数

25Mar

CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia彩票有几个球几个数

24Mar

CymaBay Therapeutics Appoints Robert J. Wills, Ph.D. to Board of Directors彩票有几个球几个数

23Mar

CymaBay Therapeutics to Host Key Opinion Leader Meeting on March 27 in New York City彩票有几个球几个数

18Mar

CymaBay Reports Fourth Quarter and Full Year 2014 Financial Results彩票有几个球几个数

11Mar

CymaBay Therapeutics to Announce Fourth Quarter and Year-End 2014 Financial Results and Business Update on Wednesday, March 18, 2015彩票有几个球几个数

27Feb

CymaBay to Present at Upcoming Investor Conferences彩票有几个球几个数

24Feb

CymaBay Therapeutics Announces Positive Results From Its Phase 2b Clinical Study Demonstrating That Arhalofenate Met the Primary Endpoint of Reduction in Gout Flares彩票有几个球几个数

4Feb

CymaBay to Present at 17th Annual BIO CEO & Investor Conference彩票有几个球几个数

28Jan

CymaBay Therapeutics Announces Preclinical Data Demonstrating the Potential of MBX-8025 to Treat Homozygous Familial Hypercholesterolemia彩票有几个球几个数

12Jan

Cymabay Therapeutics Announces Positive Results From Its Phase 2 Clinical Study of Arhalofenate in Combination With Febuxostat彩票有几个球几个数

26Nov

CymaBay Therapeutics to Present at the Piper Jaffray 26th Annual Healthcare Conference彩票有几个球几个数

12Nov

CymaBay Reports Third Quarter 2014 Financial Results彩票有几个球几个数

31Oct

CymaBay Therapeutics to Announce Third Quarter 2014 Financial Results on Wednesday, November 12, 2014彩票有几个球几个数

15Oct

CymaBay Therapeutics to Participate in Two Upcoming Investor Conferences彩票有几个球几个数

29Sep

CymaBay Completes Enrollment in its Phase 2b Study of Arhalofenate in Patients with Gout彩票有几个球几个数

28Jul

CymaBay Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares彩票有几个球几个数

22Jul

CymaBay Therapeutics Announces Pricing of Public Offering of Common Stock彩票有几个球几个数

17Jul

CymaBay Therapeutics Announces Proposed Offering of Common Stock彩票有几个球几个数

16Jun

CymaBay Therapeutics Announces Uplisting to the NASDAQ Capital Market Under the Symbol "CBAY"彩票有几个球几个数

2Jun

CymaBay Therapeutics to Present at Upcoming Conferences彩票有几个球几个数

26Mar

CymaBay Initiates Arhalofenate Phase 2b Gout Study彩票有几个球几个数

3Mar

CymaBay Therapeutics Appoints Pol Boudes M.D. to Position of Chief Medical Officer彩票有几个球几个数

25Feb

CymaBay Therapeutics to Present at Cowen and Roth Investor Conferences彩票有几个球几个数

3Feb

CymaBay to Present at 16th Annual Bio CEO & Investor Conference彩票有几个球几个数

24Jan

CymaBay Therapeutics Announces Listing on OTCBB and OTC Link彩票有几个球几个数

13Jan

Sujal Shah Appointed Chief Financial Officer of CymaBay Therapeutics彩票有几个球几个数

11Dec

CymaBay Therapeutics, Inc. Completes Financing彩票有几个球几个数

10Dec

Metabolex Undergoes Capital Restructure and Renames as CymaBay Therapeutics彩票有几个球几个数

8Dec

Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat彩票有几个球几个数

29Nov

Metabolex Gout Program Recognized in Windhover's Top 10 Most Interesting Projects to Watch彩票有几个球几个数

1Nov

Metabolex to Present Data on Arhalofenate, a Potential Novel Treatment for Gout, at the 2011 ACR/ARHP Annual Scientific Meeting彩票有几个球几个数

19May

Metabolex Initiates Phase 2 Trial of Arhalofenate彩票有几个球几个数

22Jun

Metabolex Enters Into Type 2 Diabetes Development and License Agreement彩票有几个球几个数

RSS
彩票王者txt下载彩票双色球中奖金额彩票万能准确选号器彩票淘宝彩票头条app彩票双色球有多少种组合